Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | SCYX SCYNEXIS, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $4.94 +6.0% | $16.31 +6.3% |
| StockIQ Score | 53C- Moderate Risk: Medium | 42D Weak Risk: Medium |
| Technical | 36F | 36F |
| Fundamental | 39F | 35F |
| Growth | 74B | 50C- |
| Fair Value | 55C | 38F |
| News | 86A | 50C- |
| Quality | 63C+ | 50C- |
| Risk | 46D+ | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
SCYNEXIS (SCYX) outperforms Ascentage Pharma (AAPG) in most categories. Its growth score of 74 is significantly higher than AAPG’s 50, showing stronger expected expansion. SCYX also has a moderate rating versus AAPG’s weak, though both share equal technical scores of 36. Valuation and fundamentals favor SCYX slightly, with scores of 55 and 39 compared to 38 and 35.
